


Supplementary information

**Ultra-long-acting removable drug delivery system for
HIV treatment and prevention**

Kovarova et al

Supplementary Materials:



Supplementary Figure 1: Comparison of pharmacological profiles of ultra-LA DTG in

NSG and BLT mice. NSG (n=3) or BLT (n=5) mice received subcutaneously 233 mg/kg and 250 mg/kg of ultra-long-acting dolutegravir, respectively. Plasma dolutegravir concentration was evaluated longitudinally for 2 months after ultra-long-acting dolutegravir administration.

Concentration of DTG in plasma of individual mice are shown. Experiment was conducted once.

Supplementary Table 2: Sequences of primers used in the study

Use of the primer	Sequence of primer
Generation of HIV <i>gag</i> cDNA	5'-CTTCCAATTATGTTGACAGGTGTAGG-3'
Nested PCR of <i>gag</i> ; outer forward primer	5'-CTCAATAAAGCTTGCCTTGAGTGC-3';
Nested PCR of <i>gag</i> ; outer reverse primer	5'-CTTCCAATTATGTTGACAGGTGTAGG-3';
Nested PCR of <i>gag</i> ; inner forward primer	5'-GTGTGGAAAATCTCTAGCAGTGGC-3';
Nested PCR of <i>gag</i> ; inner reverse primer	5'-CTGTATCATCTGCTCCTGTATCTAATAGAGC-3'
Generation of HIV integrase cDNA	5'- GGTCAGGGTCTACTTGTGTGC -3'
Nested PCR of integrase; outer forward primer	5'- CCTGAGTGGGAGTTTGTCAATAC -3'
Nested PCR of integrase; outer reverse primer	5'- GGTCAGGGTCTACTTGTGTGC -3'
Nested PCR of integrase; inner forward primer	5'- AGCACACAAAGGAATTGGAG -3'
Nested PCR of integrase; inner reverse primer	5'- GTGGGATTTGTA CT TCTGAAC -3'
Forward primer for HIV-RNA and DNA amplification	5'- CATGTTTTTCAGCATTATCAGAAGGA-3'
Reverse primer for HIV-RNA and DNA amplification	5'- TGCTTGATGTCCCCCACT-3'
Forward primer for human gamma globin DNA amplification	5'- CGCTTCTGGAACGTCTGAGATT-3'
Reverse primer for human gamma globin DNA amplification	5'- CCTTGTCCCTCCTCCTGTGAAATGA -3'